KVUE Kenvue
Iconic consumer-health brands at a fair, deal-anchored price; standalone value depends on margin recovery.
The story
Kenvue is the world's largest pure-play consumer health company (Tylenol, Listerine, Neutrogena, Band-Aid, Zyrtec), with durable brand moats, pharmacist and physician recommendation, and OTC regulatory barriers. It is a mature, low-growth business that has been fixing underinvestment in skin health and absorbing Tylenol litigation headlines, with activist pressure and the pending Kimberly-Clark acquisition (cash plus stock) anchoring the market price. On a standalone basis it is a steady cash generator whose upside depends on restoring margins toward peer consumer-health levels.
Growth of 2-3% matches category growth plus modest pricing, with a terminal rate well below the risk-free rate. A 19.5% target margin assumes partial recovery toward Haleon-like consumer-health economics (~21-22%) as restructuring and the skin-health reset land, while staying below peak. Reported sales-to-capital of 0.8 is distorted by J&J-era goodwill, so incremental reinvestment is set at 1.6. Beta of 0.75 sits near the staples anchor, raised slightly for leverage and litigation exposure.
Value drivers
| Revenue growth (Y1) | 2.5% |
| Terminal growth | 2.5% |
| Forecast horizon | 7y |
| Target operating margin | 19.5% |
| Years to target margin | 5 |
| Sales-to-capital | 1.60 |
| Beta | 0.75 |
| Failure probability | 2.0% |
| Cost of capital (WACC) | 8.0% |
| Terminal WACC | 8.9% |
Valuation bridge
| PV of explicit FCFF | 10.79B |
| PV of terminal value | 18.35B |
| Equity value | 21.38B |
| ÷ shares → per share | $11.13 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 15.79B | 2.5% | 17.6% | 2.05B | 240.75M | 1.81B | 1.67B |
| 2 | 16.19B | 2.5% | 18.1% | 2.16B | 246.77M | 1.91B | 1.64B |
| 3 | 16.59B | 2.5% | 18.6% | 2.27B | 252.94M | 2.01B | 1.60B |
| 4 | 17.01B | 2.5% | 19.0% | 2.38B | 259.26M | 2.12B | 1.56B |
| 5 | 17.43B | 2.5% | 19.5% | 2.50B | 265.74M | 2.23B | 1.52B |
| 6 | 17.87B | 2.5% | 19.5% | 2.56B | 272.39M | 2.29B | 1.44B |
| 7 | 18.32B | 2.5% | 19.5% | 2.63B | 279.20M | 2.35B | 1.37B |
Key risks
- Tylenol/acetaminophen litigation and regulatory or reputational fallout
- Skin health and beauty share losses to indie and derm brands
- Kimberly-Clark deal break or renegotiation removing the takeover floor in the price
- Private-label erosion and retailer destocking in OTC categories
Catalysts
- Closing of the Kimberly-Clark acquisition and realization of cost synergies
- Margin recovery from restructuring and the brand reinvestment program
- Favorable resolution or dismissal of acetaminophen-related claims